Oxymetholone 50 mg

Oxymetholone 50 mg contains oxymetholone, which is FDA-approved for the treatment of anemias caused by deficient red cell production, including acquired aplastic anemia, congenital aplastic anemia, myelofibrosis, and hypoplastic anemias due to myelotoxic drugs. It is not approved for weight gain for cosmetic reasons or to develop muscle mass in otherwise healthy patients.

FDA-approved dosing is 1 to 5 mg/kg daily for anemia, with the usual effective dosage being 1 to 2 mg/kg daily. Response often is not immediate; a minimum trial of 3 to 6 months is recommended. In non-medical bodybuilding contexts, oxymetholone is commonly referenced at 25–100 mg daily for 4–8 weeks. No dosing recommendation can be made for this research chemical product, as it is not FDA-approved for human use in the form sold.

Oxymetholone suppresses endogenous testosterone production, and post-cycle therapy is commonly recommended in non-medical contexts. Agents such as Clomid or Tamoxifen are commonly referenced for this purpose. Given oxymetholone's short half-life of 8–9 hours, PCT can begin within 2–3 days of the last dose. A typical PCT protocol referenced in bodybuilding contexts includes Clomid 50 mg/day or Nolvadex 20 mg/day for 4 weeks.

Oxymetholone stimulates erythropoiesis and enhances erythropoietin production in patients with bone marrow failure. As an anabolic steroid, it promotes nitrogen retention and protein synthesis, which can help patients maintain body weight during severe illness. It is a 17-alpha-alkylated derivative of testosterone that can be administered orally.

For its FDA-approved anemia indication, response often is not immediate; a minimum trial of 3 to 6 months is recommended. The plasma half-life is approximately 8–9 hours. In non-medical contexts, community reports suggest initial changes in weight and strength may be noticed within 1–2 weeks, with more pronounced effects by week 3–4.

There is no clinical evidence to establish oxymetholone as superior to other compounds for non-medical use. Oxymetholone is considered highly potent and can lead to significant increase in muscle mass, but this quick increase can lead to tendon rupture from the increased load. It is associated with serious hepatotoxicity and cardiovascular risks, and is not FDA-approved for non-medical use.

Oxymetholone and Anavar (oxandrolone) are both oral anabolic steroids, but they have different FDA-approved indications and side effect profiles. Oxymetholone is approved for anemia and carries black box warnings for peliosis hepatis and liver cell tumors. Oxandrolone is approved for different indications and is not associated with the same black box warnings. Both are 17-alpha-alkylated and carry hepatotoxicity risks.

Oxymetholone and Danabol (methandienone) are both 17-alpha-alkylated oral anabolic steroids. Oxymetholone is FDA-approved for specific anemia indications, while methandienone is not FDA-approved for any human use in the United States. Both are associated with significant hepatotoxicity and are banned in sport.

A milligram amount cannot be classified as appropriate or excessive without considering the medical indication, individual response, and other factors. FDA-approved dosing for anemia is 1 to 5 mg/kg daily. It is also important to distinguish a dose from a product's tablet strength. Oxymetholone 50 mg indicates 50 mg per tablet; that strength does not by itself specify how much should be taken.

Oxymetholone 50 mg is labeled at 50 mg of oxymetholone per tablet. It is supplied as oral tablets in a 100-tablet package.

Yes. A published laboratory report dated October 22, 2024 measured Oxymetholone 50 mg at 50.09 mg, equivalent to 100.18% of its 50 mg label claim. The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report.

In non-medical bodybuilding contexts, oxymetholone is sometimes stacked with injectable testosterone or other anabolic compounds. However, oxymetholone is not FDA-approved for non-medical use, and no clinical data exists to support any combination with other compounds. Because oxymetholone is 17-alpha-alkylated, concurrent use with other oral 17-alpha-alkylated steroids increases hepatotoxicity risk.